DOCSLIB.ORG

What's New in Eczema Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What's New in Eczema Management What’s New in Eczema Management: Practice Pearls for the Family Physician This educational activity is jointly provided by the North Carolina Academy of Family Physicians (NCAFP) and Spire Learning. This activity is supported by an educational grant from Pfizer Inc. What’s New in Eczema Management: Practice Pearls for the Family Physician PROGRAM OVERVIEW This live meeting series will address the latest in the care and management of pediatric and adult dermatitis as well as strategies to individualize treatment. TARGET AUDIENCE Family physicians LEARNING OBJECTIVES At the conclusion of this live activity, family physicians should be better able to: • Recognize the clinical features and characteristic age distribution patterns of atopic dermatitis (AD) • Describe the role of skin barrier dysfunction, immune dysregulation, and environmental factors in the pathogenesis of AD • Individualize AD management regimens according to age, location, disease severity, response to treatment, and quality-of-life (QOL) concerns • Educate patients and families about the safe and appropriate use of skin-directed therapies for the treatment of AD ACCREDITATION AND DISCLAIMER STATEMENTS This live activity, What’s New in Eczema Management: Practice Pearls for the Family Physician has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AMA/AAFP Equivalency: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1. What’s New in Eczema Management: Practice Pearls for the Family Physician HOW TO RECEIVE CREDIT To receive credit for your participation in this educational activity: • Read the objectives and other introductory CME information • Complete the preassessment prior to the start of the activity • Participate in the atopic dermatitis (eczema) presentation • Complete the postassessment and evaluation at the conclusion of the activity If you are seeking Prescribed credit, you must complete the postassessment and evaluation at the conclusion of the activity. LEVELS OF EVIDENCE Levels of evidence are provided for any patient care recommendations made during this presentation. Level A (randomized controlled trial/meta-analysis): High-quality, randomized controlled trial (RCT) that considers all important outcomes. High-quality meta-analysis (quantitative systematic review) using comprehensive search strategies Level B (other evidence): A well-designed, nonrandomized clinical trial. A nonquantitative systematic review with appropriate search strategies and well-substantiated conclusions. Includes lower-quality RCTs, clinical cohort studies, and case-controlled studies with nonbiased selection of study participants and consistent findings. Other evidence, such as high-quality, historical, uncontrolled studies, or well-designed epidemiologic studies with compelling findings, is also included Level C (consensus/expert opinion): Consensus viewpoint or expert opinion Each rating is applied to a single reference in the presentation, not the entire body of evidence on the topic. OFF-LABEL STATEMENT The faculty will discuss non–FDA-approved or investigational agents for the treatment of AD (eczema), including anti-IL-31, apremilast, fezakinumab, lebrikizumab, OPA-154062, roflumilast, SB011, tofacitinib ointment, tralokinumab, and ustekinumab. Participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this activity. What’s New in Eczema Management: Practice Pearls for the Family Physician FACULTY PRESENTERS Activity Chair: Anthony J. Mancini, MD, FAAP, FAAD Head, Division of Pediatric Dermatology Ann & Robert H. Lurie Children’s Hospital of Chicago Professor of Pediatrics and Dermatology Northwestern University Feinberg School of Medicine Chicago, IL Anthony J. Mancini, MD, FAAP, FAAD, is Professor of Pediatrics and Dermatology at Northwestern University Feinberg School of Medicine and Head of the Division of Pediatric Dermatology at Ann & Robert H. Lurie Children’s Hospital of Chicago, where he directs the division’s pediatric dermatology fellowship training program. Dr Mancini received his medical degree at the University of Arizona, and trained in pediatrics, pediatric dermatology, and dermatology at Stanford University, California. He is a Fellow of both the American Academy of Dermatology and the American Academy of Pediatrics (AAP). Dr Mancini’s clinical and research interests include infantile hemangiomas, atopic dermatitis, exanthems of childhood, and neonatal skin maturation and skin disorders. He has published 215 peer-reviewed articles, abstracts, books, and book chapters. He is coauthor of Hurwitz Clinical Pediatric Dermatology (3rd, 4th, 5th, and the upcoming 6th editions), coeditor of the AAP publication, Pediatric Dermatology – A Quick Reference Guide (1st, 2nd, and 3rd editions), and Pediatric Section Editor of Dermatology (1st, 2nd, and 3rd editions). Dr Mancini is the past President of the Society for Pediatric Dermatology, where he also served for 10 years as Secretary-Treasurer, and past Chair of the 2017 World Congress of Pediatric Dermatology. He previously served on the AAP Executive Committee of the Section on Dermatology, the AAP Super CME Planning Group, and the AAP PediaLink Pediatric Dermatology Project Team. Dr Mancini is an author of the upcoming AAP Clinical Practice Guidelines on Infantile Hemangiomas. Disclosure Statement: Advisory Board: Pfizer Inc Consultant: Pfizer Inc What’s New in Eczema Management: Practice Pearls for the Family Physician FACULTY PRESENTERS (CONT’D) Jane Sanders Bellet, MD, FAAD Associate Professor of Dermatology Associate Professor of Pediatrics Duke University School of Medicine Durham, NC Jane Sanders Bellet, MD, FAAD, is an Associate Professor in the Departments of Dermatology and Pediatrics at Duke University School of Medicine in Durham, North Carolina. She is also Founder and Director of the Duke Nail Clinic. Dr Bellet received her medical degree from the University of Cincinnati College of Medicine in Cincinnati, Ohio. She trained in pediatrics and dermatology at Duke University School of Medicine, and completed a fellowship in pediatric dermatology at Children’s Memorial Hospital of Northwestern University in Chicago, Illinois. Dr Bellet cares for all pediatric skin conditions and specializes in the treatment of hemangiomas, port wine stains, vascular malformations, hyperhidrosis, and nail abnormalities. She is a frequent lecturer on these topics and has published widely, including peer-reviewed articles, invited reviews, and book chapters. Dr Bellet serves on committees for the Society for Pediatric Dermatology and the American Academy of Dermatology at Duke University Health System. She was presented with the Strength, Hope, and Caring Award in 2016. This annual award is presented to employees whose extraordinary care embodies the ideals of the Duke University Health System through compassionate support of patients, their families, and fellow employees. Disclosure Statement: Advisory Board: Pfizer Inc What’s New in Eczema Management: Practice Pearls for the Family Physician FACULTY PRESENTERS (CONT’D) Lucia Z. Diaz, MD Chief of Pediatric and Adolescent Dermatology Dermatology Residency Associate Program Director Assistant Professor of Medicine and Pediatrics University of Texas Dell Medical School Austin, TX Lucia Z. Diaz, MD, is Chief of Pediatric and Adolescent Dermatology, Dermatology Residency Associate Program Director, and an Assistant Professor of Medicine and Pediatrics at the University of Texas Dell Medical School in Austin, Texas. She is also Co-director of the Dermatology-Rheumatology Combined Clinic at Dell Children’s Medical Center. Dr Diaz received her medical degree from the University of Texas Health Science Center in San Antonio, Texas, where she also completed a pediatric internship. She subsequently completed a dermatology residency at the University of Texas Medical School/MD Anderson Cancer Center in Houston, Texas, and a pediatric dermatology fellowship at the University of California, San Diego Medical School/Rady Children’s Hospital in San Diego, California. Dr Diaz’s clinical interests include birthmarks, rheumatologic conditions, severe inflammatory skin diseases, and procedural dermatology. She is a frequent lecturer on these topics and other areas of pediatric and general dermatology. Dr Diaz has numerous publications to her credit, including peer-reviewed articles, abstracts, and book chapters. She is an active and longstanding member of several professional societies, including the American Academy of Dermatology, the Pediatric Dermatology Research Alliance, the Society for Pediatric Dermatology, the Women’s Dermatology Society, and the American Society for Laser Medicine and Surgery. Dr Diaz enjoys working with children and discovering the long-lasting impact one can make on a child’s mental and physical health through patient education and advocacy, in addition to medical treatments. She has won multiple awards for teaching and clinical care and has been named “Super Doctor Rising Star” for the past 2 years. Disclosure Statement: No relevant financial relationships with any
Load more

Recommended publications
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • BIOLOGIC THERAPIES ASTHMA DYKEWICZ F BW.Pdf
    11/30/2011 Biologic Asthma Therapies and Individualized Medicine Disclosures Advisory boards Mark S. Dykewicz, MD Merck (advisor, honorarium) Director, Allergy & Immunology Shire (advisor, honorarium) Fellowship Program Director Wake Forest University School of Medicine Editorial boards Winston-Salem, North Carolina USA Allergy & Asthma Proceedings American Journal of Rhinology & Allergy Clinical Reviews in Allergy & Immunology Journal of Angioedema Learning Objective Biological therapies May fill unmet needs, potentially in To better understand the use of biologic subpopulations or phenotypes of patients with modifiers in individualized asthma more severe asthma. treatment. May provide insight into mechanisms of asthma Sheharyar, Durrani, Busse. Biological Therapy for Asthma. ACCP PCCSU Article | 03.15.11 Omalizumab (Anti-IgE) Biologics with action against IgE (omalizumab) Biologic mechanism: Mab against IgE; decreases IgE Cytokines levels; results in down-regulation of IgE receptor IL-4 and/or IL-13 Patient subsets: persistent asthma selected for IL-5 specific IgE to perennial allergen, total serum IgE in Chemokine Receptors specified range CCR3 Benefits: 8 trials (n=3429) Rodrigo. Chest 2011 139:28 CXCR2 decreases in exacerbations, dose of inhaled and oral Transcription Factors corticosteroids, hospitalizations PPARs (peroxisome proliferator-activated receptors) improvement in QOL when used as add-on Rx Prostaglandin Receptors no improvement in lung function. CRTH2 6 1 11/30/2011 IL-4 Modifiers IL-13 Altrakincept Solubilized IL-4 Failed to show efficacy in large phase Pleiotropic cytokine of Th2 cells, promotes IgE receptor fragment, 3 trial. production neutralizes IL-4 Adcock et al (2008) May contribute to key features of asthma Pascolizumab Monoclonal Ab Phase 2 study of pascolizumab IL-13 production inhibited by inhaled glucocorticoids against IL- 4 discontinued because of inefficacy.
    [Show full text]
  • Biological Therapies for Atopic Dermatitis: an Update (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 1061-1067, 2019 Biological therapies for atopic dermatitis: An update (Review) DIANA DELEANU1-3 and IRENA NEDELEA1,2 1Allergology and Immunology Discipline, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400058 Cluj-Napoca; Departments of 2Allergy and 3Internal Medicine, ‘Professor Doctor Octavian Fodor’ Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania Received July 6, 2018; Accepted August 22, 2018 DOI: 10.3892/etm.2018.6989 Abstract. Severe atopic dermatitis, which affects both adults in low-income countries (3). Furthermore, the past decades and children, is a debilitating disorder with a significant decline brought a 2-3-fold increase in prevalence in industrialized of patients' quality of life. Although aetiopathogenic factors countries (3). Generally AD onset is in early childhood, as are currently a topic of study and interpretation, the main one of the first steps of the ‘atopic march’, which describes the features of atopic eczema are skin barrier disturbance and natural history of atopic manifestations, and it is character- immune dysregulation. Severe refractory disease that fails to ized by xerotic skin and acute flare-ups of intensely pruritic improve with conventional therapy may benefit from biologic eczematous lesions (4). Recent studies recognize a predilection therapy. Progress in understanding immunopathology of atopic of AD for persistence in adulthood, with a lifetime prevalence dermatitis have allowed identification of therapeutic molecular accounting for 34.1% (5). Early onset, allergic rhinitis and targets in the field of biological therapy. We reviewed the hand eczema in childhood are high-risk factors for persistent different biological treatments with a focus on novel targeted AD (5).
    [Show full text]
  • Evaluation of Antibody Properties and Clinically Relevant Immunogenicity
    Drug Safety https://doi.org/10.1007/s40264-018-00788-w ORIGINAL RESEARCH ARTICLE Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma Mats Carlsson1 · Martin Braddock2 · Yuling Li3 · Jihong Wang3 · Weichen Xu3 · Nicholas White4 · Ayman Megally5 · Gillian Hunter6 · Gene Colice5 © The Author(s) 2019 Abstract Introduction Tralokinumab is a monoclonal antibody (mAb) that neutralizes interleukin (IL)-13, a cytokine involved in the pathogenesis of asthma. Objective The objectives of this study were to characterize the potential immunogenic properties of tralokinumab and report data for anti-drug antibodies (ADAs) and hypersensitivity reactions from two phase III clinical trials. Methods The oligosaccharide structure of tralokinumab, Fab-arm exchange, and ADAs were characterized by standard techniques. Hypersensitivity adverse events (AEs) were evaluated in two pivotal clinical trials of tralokinumab in severe, uncontrolled asthma: STRATOS 1 and 2 (NCT02161757 and NCT02194699). Results No galactose-α-1,3-galactose (α-Gal) epitopes were found in the Fab region of tralokinumab and only 4.5% of glycoforms contained α-Gal in the Fc region. Under non-reducing conditions, Fab-arm exchange did not take place with another immunoglobulin (Ig) G­ 4 mAb (mavrilimumab). However, following glutathione reduction, a hybrid antibody with monovalent bioactivity was detected. ADA incidences (titers) were as follows: STRATOS 1—every 2 weeks (Q2 W) 0.8% (26.0), every 4 weeks (Q4 W) 0.5% (26.0), placebo 0.8% (52.0); STRATOS 2—Q2 W 1.2% (39.0), placebo 0.8% (13.0). Participant-reported hypersensitivity AE rates were as follows: STRATOS 1—Q2 W 25.9%, Q4 W 25.0%, placebo 25.5%; STRATOS 2—Q2 W 13.2%, placebo 9.0%.
    [Show full text]
  • Anticorps FR-EN 110X90.Indd
    MONOCLONAL ANTIBODIES and Fc fusion proteins for therapeutic use DISTRIBUTION OF INTERNATIONAL NONPROPRIETARY NAMES BY INDICATION SOLID TUMORS RHUMATOLOGY PNEUMOLOGY Lung cancer bevacizumab Rheumatoid arthritis etanercept Allergic asthma omalizumab nivolumab infliximab Severe eosinophilic asthma mepolizumab necitumumab adalimumab reslizumab atezolizumab rituximab Colorectal cancer bevacizumab abatacept TRANSPLANTATION cetuximab tocilizumab Transplant rejection basiliximab panitumumab certolizumab pegol belatacept aflibercept golimumab Graft versus host disease inolimomab Bladder cancer atezolizumab Psoriatic arthritis etanercept Breast cancer trastuzumab adalimumab OPHTALMOLOGY bevacizumab infliximab Age related macular ranibizumab pertuzumab golimumab degeneration aflibercept trastuzumab entansine ustekinumab bevacizumab Gastric cancer trastuzumab certolizumab pegol Macular edema ranibizumab ramucirumab secukinumab aflibercept Head and neck cancer cetuximab Ankylosing spondylitis infliximab Myopic choroidal ranibizumab Ovarian cancer bevacizumab etanercept neovascularization aflibercept Fallopian tube cancer bevacizumab adalimumab Cervical cancer bevacizumab golimumab HAEMOSTASIS AND THROMBOSIS Kidney cancer bevacizumab certolizumab pegol nivolumab secukinumab Haemophilia A efmoroctocog α Melanoma ipilimumab Juvenile arthritis etanercept Haemophilia B eftrenonacog α nivolumab adalimumab Reversal of dabigatran idarucizumab Idiopathic thrombocytopenic pembrolizumab abatacept romiplostim Neuroblastoma dinutuximab tocilizumab purpura Malignant
    [Show full text]
  • New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair Via the Regulation of FLG Expression
    Journal of Clinical Medicine Review New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression Anna D˛ebi´nska 1st Department and Clinic of Paediatrics, Allergology and Cardiology, Wroclaw Medical University, Chałubi´nskiego2a, 50-368 Wrocław, Poland; [email protected]; Tel.: +48-510-066-478 or +71-770-30-91; Fax: +48-713-281-206 Abstract: Atopic dermatitis (AD) is one of the most common chronic, inflammatory skin disorders with a complex etiology and a broad spectrum of clinical phenotypes. Despite its high prevalence and effect on the quality of life, safe and effective systemic therapies approved for long-term management of AD are limited. A better understanding of the pathogenesis of atopic dermatitis in recent years has contributed to the development of new therapeutic approaches that target specific pathophysiological pathways. Skin barrier dysfunction and immunological abnormalities are critical in the pathogenesis of AD. Recently, the importance of the downregulation of epidermal differentiation complex (EDC) molecules caused by external and internal stimuli has been extensively emphasized. The purpose of this review is to discuss the innovations in the therapy of atopic dermatitis, including biologics, small molecule therapies, and other drugs by highlighting regulatory mechanisms of skin barrier-related molecules, such as filaggrin (FLG) as a crucial pathway implicated in AD pathogenesis. Keywords: atopic dermatitis; skin barrier; filaggrin; biologicals; small molecule therapies Citation: D˛ebi´nska,A. New Treatments for Atopic Dermatitis 1. Introduction Targeting Skin Barrier Repair via the Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disor- Regulation of FLG Expression.
    [Show full text]
  • Safety of Specifically Targeting Interleukin 13 with Tralokinumab In
    Safety of specifically targeting interleukin 13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled Phase 3 and Phase 2 trials Eric Simpson,1 Joseph F Merola,2 Jonathan I Silverberg,3 Rebecca Zachariae,4 Christina Kurre Olsen,4 Andreas Wollenberg5 1Department of Dermatology, Oregon Health & Science University, Portland, OR, USA; 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; 3Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; 4LEO Pharma A/S, Ballerup, Denmark; 5Klinikum der Universität München, Klinik und Poliklinik für Dermatologie und Allergologie, Munich, Germany ● AEs are summarised by the number and proportion of patients with AEs and the number and rate of Safety: monotherapy pool events by treatment group Table 3. Overall safety summary (safety analysis set, initial treatment period) ● Medical Dictionary for Regulatory Activities (MedDRA) version 2.0 was used (initial and maintenance treatment period) Introduction ● The overall frequency of AEs during the initial treatment period was similar for tralokinumab (69.0%) ● Event rates are presented as the number of events per 100 patient-years of exposure (PYE) AD pool Monotherapy pool and placebo (71.5%) and similar to the AD pool (Table 3) ● Atopic dermatitis (AD) is a chronic, debilitating, inflammatory skin disease1,2 characterised by Statistical analysis — The majority of AEs were mild
    [Show full text]
  • Atopic Dermatitis (AD)
    This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by education grants from AbbVie, Inc., Sanofi Genzyme and Regeneron Pharmaceuticals. © 2019 PRIME® Education, LLC. All Rights Reserved.. Overview This downloadable fact‐sheet provides an easy‐to‐follow collection of the latest evidence shaping the treatment and management of psoriasis (PsO) and atopic dermatitis (AD). Learn about validated tools, evidence‐based strategies, and new and emerging targeted therapies that can be incorporated in daily practice to improve outcomes for patients with these conditions. © 2019 PRIME® Education, LLC. All Rights Reserved.. 2 1 Learning Objectives • Identify major barriers to evidence‐based treatment and management in federal and public sectors • Implement appropriate methods for diagnosis and assessment of disease activity • Assess current evidence on targeted biologic and small‐molecule therapies to guide treatment decisions for patients with moderate to severe disease • Monitor treatment responses according to treat‐to‐target principles and methods • Apply current evidence and guidelines to inform treatment decisions for patients with inadequate responses to initial therapies • Incorporate patient‐reported outcomes and shared decision‐making into clinical practice • Apply effective strategies for multidisciplinary care coordination and shared patient management © 2019 PRIME® Education, LLC. All Rights Reserved.. 3 Accreditation In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team, and learners will receive 2.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
    [Show full text]
  • Atopic Dermatitis: an Expanding Therapeutic Pipeline for a Complex Disease
    REVIEWS Atopic dermatitis: an expanding therapeutic pipeline for a complex disease Thomas Bieber 1,2,3 Abstract | Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates. In addition to regulatory approval for the IL-4Ra inhibitor dupilumab, the anti- IL-13 inhibitor tralokinumab and the JAK1/2 inhibitor baricitinib in Europe, there are now more than 70 new compounds in development. This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease. Atopic disorders Atopic dermatitis (AD) is the most common chronic inhibitors tacrolimus and pimecrolimus and more 1,2 A group of disorders having in inflammatory skin disease . About 80% of disease cases recently the phosphodiesterase 4 (PDE4) inhibitor cris- common a genetic tendency to typically start in infancy or childhood, with the remain- aborole. For the more severe forms of AD, besides the develop IgE- mediated allergic der developing during adulthood. Whereas the point use of ultraviolet light, current therapeutic guidelines reactions. These are atopic dermatitis, food allergy, allergic prevalence in children varies from 2.7% to 20.1% across suggest ciclosporin A, methotrexate, azathioprine and 3,4 rhino- conjunctivitis and countries, it ranges from 2.1% to 4.9% in adults .
    [Show full text]
  • Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: a Free Assay Disguised As Total
    pharmaceutics Article Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total John Hood 1,*, Ignacio González-García 1 , Nicholas White 1, Leeron Marshall 1,2, Vincent F. S. Dubois 1 , Paolo Vicini 1,3 and Paul G. Baverel 1,4 1 Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge CB21 6GH, UK; [email protected] (I.G.-G.); [email protected] (N.W.); [email protected] (L.M.); [email protected] (V.F.S.D.); [email protected] (P.V.); [email protected] (P.G.B.) 2 Salford Royal Foundation Trust, Salford M6 8HD, UK 3 Confo Therapeutics, 9052 Ghent, Zwijnaarde, Belgium 4 Roche Pharma Research and Early Development, Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland * Correspondence: [email protected]; Tel.: +44-1223-749-6288 Abstract: A sequential pharmacokinetic (PK) and pharmacodynamic (PD) model was built with Nonlinear Mixed Effects Modelling based on data from a first-in-human trial of a novel biologic, MEDI7836. MEDI7836 is a human immunoglobulin G1 lambda (IgG1λ-YTE) monoclonal antibody, Citation: Hood, J.; González-García, with an Fc modification to reduce metabolic clearance. MEDI7836 specifically binds to, and function- I.; White, N.; Marshall, L.; Dubois, ally neutralizes interleukin-13. Thirty-two healthy male adults were enrolled into a dose-escalation V.F.S.; Vicini, P.; Baverel, P.G. clinical trial. Four active doses were tested (30, 105, 300, and 600 mg) with 6 volunteers enrolled Pharmacokinetic-Pharmacodynamic per cohort. Eight volunteers received placebo as control.
    [Show full text]